Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer
Clin. transl. oncol. (Print)
; Clin. transl. oncol. (Print);18(7): 722-727, jul. 2016. ilus, graf
Article
in En
| IBECS
| ID: ibc-153498
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Lung cancer, the most common malignancy, is still the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) accounts for 80 % of all lung cancers. Recent studies showed Cathepsin L (CTSL) is overexpressed in various cancerous tissues; however, the association between CTSL expression and EGFR-TKI resistance remains unknown. In this study, we investigated the expression of CTSL in lung cancer specimens and matched normal tissues by quantitative real-time PCR and IHC. The functional role of CTSL in resistant PC- 9/GR cell line was investigated by proliferation and apoptosis analysis compared with control PC-9 cells. Our results found that the level of CTSL expression was higher in NSCLC tissues compared with matched normal adjacent tissue samples, and CTSL was more highly expressed in PC-9/GR cells compared to PC-9 cells. Knocking-down of CTSL in PC-9/GR cells could decrease cell proliferation and potentiate apoptosis induced by gefitinib, suggesting CTSL may contribute to gefitinib resistance in NSCLC. CTSL might be explored as a candidate of therapeutic target for modulating EGFR-TKI sensitivity in NSCLC (AU)
RESUMEN
No disponible
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Drug Resistance
/
Carcinoma, Non-Small-Cell Lung
/
Cathepsin L
Type of study:
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2016
Document type:
Article